

Drug Utilization Review (DUR) Meeting Minutes
March 4, 2015

Members Present: John Savageau, Jeffrey Hostetter, Peter Woodrow, Russ Sobotta, Tanya Schmidt, Michael Booth, Carlotta McCleary, Laura Schield, Katie Kram, Wendy Brown, Michael Quast

Members Absent: James Carlson, Leann Ness, Steve Irsfeld

Medicaid Pharmacy Department: Brendan Joyce, Gary Betting

J. Savageau called the meeting to order at 1:00 p.m. Chair J. Savageau asked for a motion to approve the minutes from the December meeting. P. Woodrow moved that the minutes be approved, and W. Brown seconded the motion. Chair J. Savageau called for a voice vote to approve the minutes. The motion passed with no audible dissent.

Introduction of new member:

B. Joyce introduced the new board member, Dr. Michael Quast. Dr. Quast was appointed by the North Dakota Medical Association.

Budget update:

Legislative session ongoing and the budget is being reviewed. There is a new bill going through session regarding Medication Therapy Management (MTM). If passed, the MTM program could be used to manage many disease states, including patients with Hepatitis C.

Otezla review

B. Joyce reviewed Otezla with the board. K. Bergstresser, representing Celgene spoke regarding Otezla. A recommendation was made by the board to ask for specialist involved in therapy and diagnosis on the form. A motion was made by J. Hostetter to place Otezla on prior authorization. L. Schield seconded the motion. This topic will be reviewed at the next meeting.

Xtoro review

B. Joyce reviewed Xtoro with the board. A motion was made by M. Booth to place Xtoro on prior authorization. K. Kram seconded the motion. This topic will be reviewed at the next meeting.

Hemangeol review

B. Joyce reviewed Hemangeol with the board. A motion was made by M. Booth to place Hemangeol on prior authorization. W. Brown seconded the motion. This topic will be reviewed at the next meeting.

Lemtrada review

B. Joyce reviewed Lemtrada with the board. A recommendation was made by the board to ask for specialist involved in therapy. A motion was made by M. Booth to place Lemtrada on prior authorization.

Agents used to treat idiopathic pulmonary fibrosis review

B. Joyce reviewed agents used to treat idiopathic pulmonary fibrosis with the board. A recommendation was made by the board to ask for indication and specialist involved in therapy. A motion was made by P. Woodrow to place these agents on prior authorization. The motion was seconded by W. Brown. Rachel Anhorn, representing Boehringer Ingelheim, spoke regarding Ofev. Lee Ding, representing Genentech, spoke regarding Esbriet. This topic will be reviewed at the next meeting.

GLP-1 receptor agonists review

B. Joyce reviewed GLP-1 receptor agonists with the board. Brad Haas, representing AstraZeneca spoke regarding Byetta. M. Booth made a motion to place GLP-1 receptor agonists on prior authorization. K. Kram seconded the motion. This topic will be reviewed at the next meeting.

Topical therapies for onychomycosis review

B. Joyce reviewed topical therapies for onychomycosis. There was no public comment. P. Woodrow made a motion to place these agents on prior authorization. J. Hostetter seconded the motion. This topic will be reviewed at the next meeting.

Criteria recommendations

The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and are usually consistent with new indications, new drugs added, new warnings, etc. These proposed criteria will be added to the current set of criteria and will be used in future DUR cycles. W. Brown moved to approve the new criteria and M. Booth seconded the motion. Chair J. Savageau called for a voice vote. The motion passed with no audible dissent.

The next DUR Board meeting will be held June 3 in Bismarck. J. Hostetter made a motion to adjourn the meeting. W. Brown seconded. The motion passed with no audible dissent. J. Savageau adjourned the meeting.